NCT03048942
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Chemotherapy
Key Eligibility Criteria:
Gender: Female
Age: 18 Years to 99 Years (Adult), Senior)
Location of Metastases:
Additional Notes: Must have ER+ tumor(s)
Exclusions: Patients with symptomatic brain metastases confirmed with CT/MRI brain
https://ClinicalTrials.gov/show/NCT03048942